The summaries are free for public use. ARTHROS will continue to add and archive summaries of articles deemed relevant to ARTHROS by our Faculty.
| 1 | |
Complications of therapy for ANCA-associated vasculitis |
Rheumatology (Oxford). 2020 May 1;59(Suppl 3):iii74-iii78. doi: 10.1093/rheumatology/kez618. |
| 2 | |
Personalized Medicine in ANCA-Associated Vasculitis ANCA Specificity as the Guide? |
Front Immunol. 2019 Dec 6;10:2855. doi: 10.3389/fimmu.2019.02855.eCollection 2019. Zachary S Wallace 1 2 3 4, John H Stone 2 3 4 |
| 3 | |
All-cause and cause-specific mortality in ANCA-associated vasculitis: overall and according to ANCA type |
Rheumatology (Oxford). 2020 Sep 1;59(9):2308-2315. doi: 10.1093/rheumatology/kez589. Zachary S Wallace 1 2 3 4, Xiaoqing Fu 1 2 3, Tyler Harkness 1 2 3, John H Stone 2 3 4, Yuqing Zhang 1 2 3 4, Hyon Choi 2 3 4 |
| 5 | |
Long-term outcomes in elderly patients with ANCA-associated vasculitis |
Rheumatology (Oxford). 2020 May 1;59(5):1076-1083. doi: 10.1093/rheumatology/kez388. Dominic McGovern 1, Sam P Williams 1, Katrina Parsons 2, Tariq E Farrah 1 3, Peter J Gallacher 1 3, Eve Miller-Hodges 1 3, David C Kluth 1, Robert W Hunter 1 3, Neeraj Dhaun 1 3 |
| 6 | |
Therapeutic options for patients with rare rheumatic diseases: a systematic review and meta-analysis |
Orphanet J Rare Dis. 2020 Oct 31;15(1):308. doi: 10.1186/s13023-020-01576-5. Tim T A Bender 1, Judith Leyens 2, Julia Sellin 1, Dmitrij Kravchenko 3, Rupert Conrad 4, Martin Mücke 5, Matthias F Seidel 6 |
| 7 | |
Complementary Use of U.S. FDA's Adverse Event Reporting System and Sentinel System to Characterize Direct Oral Anticoagulants-Associated Cutaneous Small Vessel Vasculitis |
Pharmacotherapy. 2020 Nov;40(11):1099-1107. doi: 10.1002/phar.2468. Epub 2020 Nov 8. Mohamed Mohamoud 1, Casie Horgan 2, Efe Eworuke 3, Elizabeth Dee 2, Justin Bohn 2, Oren Shapira 2, Monica A Munoz 1, Danijela Stojanovic 4, Veronica Sansing-Foster 5, Adebola Ajao 3, Lois La Grenade 1 |
| 8 | |
Low Utility of Radiological Imaging in Evaluating Cutaneous Small-Vessel Vasculitis: A Multi-institutional Retrospective Study |
J Am Acad Dermatol. 2020 Oct 1;S0190-9622(20)32644-X. doi: 10.1016/j.jaad.2020.09.051.Online ahead of print. Andrew C Walls 1, Ryan S Din 1, Jean-Phillip Okhovat 2, Peter B Chansky 3, Robert G Micheletti 3, Arash Mostaghimi 1 |
| 9 | |
An update on the microbiome in vasculitis |
Curr Opin Rheumatol. 2021 Jan;33(1):15-23. doi: 10.1097/BOR.0000000000000758. Shahna Tariq 1, Alison H Clifford |
| 10 | |
Systemic Lupus Erythematosus-associated Retinal Vasculitis Treated with Adalimumab |
Ocul Immunol Inflamm. 2020 Nov 16;1-5. doi: 10.1080/09273948.2020.1828937.Online ahead of print. Sanjana Kuthyar 1, Alexander C Barnes 1, Javeria Bhawal 2, Joseph Christiansen 1, Jessica G Shantha 1, Steven Yeh 1 |
| 11 | |
Environmental risk factors associated with ANCA associated vasculitis: A systematic mapping review |
Autoimmun Rev. 2020 Nov;19(11):102660. doi: 10.1016/j.autrev.2020.102660. Epub 2020 Sep 15. Jennifer Scott 1, Jack Hartnett 1, David Mockler 2, Mark A Little 3 |
| 12 | |
Morbidity and Mortality of Large-Vessel Vasculitides |
Curr Rheumatol Rep. 2020 Oct 16;22(12):86. doi: 10.1007/s11926-020-00963-y. Matthew J Koster 1, Kenneth J Warrington 2, Eric L Matteson 2 |
| 13 | |
Vasculitis patient journey: a scoping review of patient experiences with vasculitis |
Clin Rheumatol. 2020 Sep 30. doi: 10.1007/s10067-020-05398-5.Online ahead of print. Navjeet Gill 1, Jan Willem Cohen Tervaert 2, Elaine Yacyshyn 3 |
| 14 | |
Adjunctive Treatment With Avacopan, an Oral C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis |
ACR Open Rheumatol. 2020 Nov;2(11):662-671. doi: 10.1002/acr2.11185. Epub 2020 Oct 31. Peter A Merkel 1, John Niles 2, Richard Jimenez 3, Robert F Spiera 4, Brad H Rovin 5, Andrew Bomback 6, Christian Pagnoux 7, Antonia Potarca 8, Thomas J Schall 8, Pirow Bekker 8, CLASSIC Investigators Collaborators
Louis-Philippe Girard, Yih Chang Chen Lin, Galina Marder, Jennifer Murphy, William Shergy, Christopher Charles Striebich, Areena Swarup, James Tumlin |
| 15 | |
CanVasc consensus recommendations for the management of antineutrophil cytoplasm antibody-associated vasculitis: 2020 update |
J Rheumatol. 2020 Sep 15;jrheum.200721. doi: 10.3899/jrheum.200721. Online ahead of print. Arielle Mendel 1, Daniel Ennis 1, Ellen Go 1, Volodko Bakowsky 1, Corisande Baldwin 1, Susanne M Benseler 1, David A Cabral 1, Simon Carette 1, Marie Clements-Baker 1, Alison Clifford 1, Jan Willem Cohen Tervaert 1, Gerard Cox 1, Natasha Dehghan 1, Christine Dipchand 1, Navjot Dhindsa 1, Leilani Famorca 1, Aurore Fifi-Mah 1, Stephanie Garner 1, Louis-Philippe Girard 1, Clode Lessard 1, Patrick Liang 1, Damien Noone 1, Jean-Paul Makhzoum 1, Nataliya Milman 1, Christian A Pineau 1, Heather N Reich 1, Maxime Rhéaume 1, David B Robinson 1, Dax G Rumsey 1, Tanveer E Towheed 1, Judith Trudeau 1, Marinka Twilt 1, Elaine Yacyshyn 1, Rae Yeung 1, Lillian Barra 1, Nader Khalidi 1, Christian Pagnoux 1 |
| 16 | |
Use and reporting of outcome measures in randomized trials for anti-neutrophil cytoplasmic antibody-associated vasculitis: a systematic literature review of randomized trials |
Semin Arthritis Rheum. 2020 Sep 29;50(6):1314-1325.doi: 10.1016/j.semarthrit.2020.09.010. Online ahead of print. Sara Monti 1, Kaitlin A Quinn 2, Robin Christensen 3, David Jayne 4, Carol Langford 5, Georgia E Lanier 6, Alfred Mahr 7, Christian Pagnoux 8, Maria Bjork Viðarsdóttir 9, Peter A Merkel 10, Gunnar Tomasson 11 |
| 17 | |
Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3 in ANCA-Associated Vasculitis |
Front Immunol. 2020 Sep 3;11:2053. doi: 10.3389/fimmu.2020.02053. eCollection 2020. Gwen E Thompson 1 2, Lynn A Fussner 3, Amber M Hummel 2, Darrell R Schroeder 2, Francisco Silva 4, Melissa R Snyder 2, Carol A Langford 5, Peter A Merkel 6 7, Paul A Monach 8, Philip Seo 9, Robert F Spiera 10, E William St Clair 11, John H Stone 12, Ulrich Specks 2 |
| 18 | |
ANCA-associated vasculitis |
Nat Rev Dis Primers. 2020 Aug 27;6(1):71. doi: 10.1038/s41572-020-0204-y. A Richard Kitching 1 2, Hans-Joachim Anders 3, Neil Basu 4, Elisabeth Brouwer 5, Jennifer Gordon 6, David R Jayne 7, Joyce Kullman 8, Paul A Lyons 7 9, Peter A Merkel 10, Caroline O S Savage 11, Ulrich Specks 12, Renate Kain 13 |
| 19 | |
ANCA-associated vasculitides: Recommendations of the French Vasculitis Study Group on the use of immunosuppressants and biotherapies for remission induction and maintenance |
Presse Med. 2020 Jul 6;49(3):104031. doi: 10.1016/j.lpm.2020.104031. Online ahead of print. Benjamin Terrier 1, Pierre Charles 2, Olivier Aumaître 3, Alexandre Belot 4, Bernard Bonnotte 5, Yoann Crabol 6, Cécile-Audrey Durel 7, Mikael Ebbo 8, Noémie Jourde-Chiche 9, Jean-Christophe Lega 10, Xavier Puéchal 11, Grégory Pugnet 12, Thomas Quemeneur 13, Camillo Ribi 14, Maxime Samson 4, Frédéric Vandergheynst 15, Loïc Guillevin 11, French Vasculitis Study Group |
| 20 | |
2020 international consensus on ANCA testing beyond systemic vasculitis |
Autoimmun Rev. 2020 Sep;19(9):102618. doi: 10.1016/j.autrev.2020.102618.Epub 2020 Jul 12. Sergey Moiseev 1, Jan Willem Cohen Tervaert 2, Yoshihiro Arimura 3, Dimitrios P Bogdanos 4, Elena Csernok 5, Jan Damoiseaux 6, Marc Ferrante 7, Luis Felipe Flores-Suárez 8, Marvin J Fritzler 9, Pietro Invernizzi 10, David Jayne 11, J Charles Jennette 12, Mark A Little 13, Stephen P McAdoo 14, Pavel Novikov 15, Charles D Pusey 14, Antonella Radice 16, Alan D Salama 17, Judith A Savige 18, Mårten Segelmark 19, Yehuda Shoenfeld 20, Renato A Sinico 21, Maria-José Sousa 22, Ulrich Specks 23, Benjamin Terrier 24, Athanasios G Tzioufas 25, Severine Vermeire 7, Ming-Hui Zhao 26, Xavier Bossuyt 27 |
| 21 | |
Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis |
Ann Rheum Dis. 2020 Jun 24;annrheumdis-2019-216863.doi: 10.1136/annrheumdis-2019-216863. Online ahead of print. Rona M Smith 1 2, Rachel Bronwen Jones 2, Ulrich Specks 3, Simon Bond 4, Marianna Nodale 4, Reem Aljayyousi 5, Jacqueline Andrews 6, Annette Bruchfeld 7, Brian Camilleri 8, Simon Carette 9, Chee Kay Cheung 10, Vimal Derebail 11, Tim Doulton 12, Lindsy Forbess 13, Shouichi Fujimoto 14, Shunsuke Furuta 15, Ora Gewurz-Singer 16, Lorraine Harper 17, Toshiko Ito-Ihara 18, Nader Khalidi 19, Rainer Klocke 20, Curry Koening 21, Yoshinori Komagata 22, Carol Langford 23, Peter Lanyon 24, Raashid Ahmed Luqmani 25, Hirofumi Makino 26, Carole McAlear 27, Paul Monach 28, Larry W Moreland 29, Kim Mynard 2, Patrick Nachman 11, Christian Pagnoux 30, Fiona Pearce 31, Chen Au Peh 32, Charles Pusey 33, Dwarakanathan Ranganathan 34, Rennie L Rhee 35, Robert Spiera 36, Antoine G Sreih 37, Vladimir Tesar 38, Giles Walters 39, Michael H Weisman 13, Caroline Wroe 40, Peter Merkel 41, David Jayne 42 2, RITAZAREM coinvestigators; RITAZAREM co-investigators
Collaborators Y Arimura, M Clarkson, J de Zoysa, T Endo, Y Hamano, H Kono, S Lawman, E Muso, K Sada, R Smith, K Suzuki, T Tsukamoto, S Uchida, A Vaglio, R Watts |
| 22 | |
Epidemiology, Time-trends and Outcomes of Serious Infections in Patients With Vasculitis: A 19-year National Study |
Arthritis Care Res (Hoboken). 2020 Jun 11.doi: 10.1002/acr.24348. Online ahead of print. Jasvinder A Singh 1 2 3, John D Cleveland 2 |
| 23 | |
Utility of the Brief Illness Perception Questionnaire to Monitor Patient Beliefs in Systemic Vasculitis |
Rheumatol. 2020 Apr 1;jrheum.190828. doi: 10.3899/jrheum.190828. Online ahead of print. Mollie N Schwartz 1, Casey A Rimland 1, Kaitlin A Quinn 1, Marcela Ferrada 1, K Bates Gribbons 1, Joel S Rosenblum 1, Wendy Goodspeed 1, Elaine Novakovich 1, Peter C Grayson 1 |
| 24 | |
Treatment Outcomes of Anti-Neutrophil Cytoplasmic Autoantibody-Associated Vasculitis in Patients Over Age 75 Years: A Meta-Analysis |
Morris AD1, Elsayed ME2, Ponnusamy A2, Rowbottom A3, Martin F4, Geetha D5, Dhaygude AP2. Am J Nephrol. 2020 Mar 11:1-9. doi: 10.1159/000506532. [Epub ahead of print] |
| 25 | |
Complications of therapy for ANCA-associated vasculitis |
Smith R1,2. Rheumatology (Oxford). 2020 Jan 20. pii: kez618. doi: 10.1093/rheumatology/kez618. [Epub ahead of print] |
| 26 | |
All-cause and cause-specific mortality in ANCA-associated vasculitis: overall and according to ANCA type |
Wallace ZS1,2,3,4, Fu X1,2,3, Harkness T1,2,3, Stone JH2,3,4, Zhang Y1,2,3,4, Choi H2,3,4. Rheumatology (Oxford). 2019 Dec 17. pii: kez589. doi: 10.1093/rheumatology/kez589. [Epub ahead of print] |
| 27 | |
Long-term outcomes in elderly patients with ANCA-associated vasculitis |
McGovern D1, Williams SP1, Parsons K2, Farrah TE1,3, Gallacher PJ1,3, Miller-Hodges E1,3, Kluth DC1, Hunter RW1,3, Dhaun N1,3. Rheumatology (Oxford). 2019 Sep 17. pii: kez388. doi: 10.1093/rheumatology/kez388. [Epub ahead of print] |
| 28 | |
Personalized Medicine in ANCA-Associated Vasculitis ANCA Specificity as the Guide? |
Wallace ZS1,2,3,4, Stone JH2,3,4. Front Immunol. 2019 Dec 6;10:2855. doi: 10.3389/fimmu.2019.02855. eCollection 2019. |
| 29 | |
Anti-neutrophil Cytoplasmic Antibodies (ANCA) as Disease Activity Biomarkers in a "Personalized Medicine Approach" in ANCA-Associated Vasculitis |
Osman MS1, Tervaert JWC2. Curr Rheumatol Rep. 2019 Dec 26;21(12):76. doi: 10.1007/s11926-019-0872-3. |
| 30 | |
Remission maintenance in ANCA-associated vasculitis: does one size fit all? |
Berti A1,2, Specks U2. Expert Rev Clin Immunol. 2019 Dec;15(12):1273-1286. doi: 10.1080/1744666X.2020.1693260. Epub 2019 Nov 24. |